Aim: Recently, calcium channel blockers (CCBs) have been reported to reduce atherosclerosis with anti-inflammatory or antiatherosclerotic effects in vivo. It is well established that monocytes and macrophages play important roles in promoting atherosclerosis. However, the effects of CCBs on macrophage activation remain unclear. The aim of this study was to evaluate the effects of azelnidipine, a dihydropyridine L-type CCB, on the activation of macrophages and to clarify the mechanisms of the effects of CCBs on atherosclerosis. . Nifedipine also reduced atherosclerotic changes in mice and rabbits 4, 5) . Additionally, azelnidipine may have antiatherosclerotic effects independent of its blood pressure-lowering actions in monkeys and mice 6) . In clinical studies, azelnidipine or amlodipine were found to reduce coronary plaque volume in patients with coronary artery disease 7) . It is well established that monocytes and macro- Hiroshi Komoda and Aya Shiraki contributed equally to this work.
Introduction
L-type calcium channel blockers (CCBs) have been widely used as antihypertensive drugs in cardiovascular medicine. They lower blood pressure mainly through vasodilation and reduction of peripheral resistance, and several clinical studies have demonstrated that they have clinical benefits in patients with cardiovascular diseases. Recently, several investigations showed that dihydropyridine CCBs reduced atherosclerosis with anti-inflammatory or antiatherosclerotic
Flow Cytometry
THP-1 cells were incubated with anti-human ICAM-1 FITC (eBioscience, BMS108FI, USA) or anti human-LOX-1 APC antibody (R&D Systems, FAB1798A, USA) for 30 min at room temperature. The cells were scanned using a FACSCalibur (BectonDickinson, USA), and fluorescence of ICAM-1 and LOX-1 positive cells was quantified and analyzed by CellQuest software (Becton-Dickinson, USA) according to the manufacturer's instructions.
Western Blotting
THP-1 cells were incubated with 10 M azelnidipine for 1 h and 50 ng/mL PMA was treated for 24 h. The cells were lysed using RIPA buffer containing NaF, trypsin inhibitor, leupeptin, -glycerophosphate, and orthovanadate. Samples of THP-1 lysate were resolved on SDS-PAGE according to a standard protocol. After being transferred to polyvinylidene difluoride membranes, the samples were immunoblotted with primary antibodies followed by secondary antibodies conjugated to horseradish peroxidase. Bands were revealed using ECL Select Western Blotting Detection Reagents (GE Healthcare, Buckinghamshire, UK) and band density was quantified using Image J software. The following primary antibodies were used: p-p38 mitogenactivated protein kinase (MAPK) antibody (#9215), p-38 MAPK antibody (#9212), stress-activated protein kinases (SAPK)/ Jun-amino-terminal kinase (JNK) (#9252), p-SAPK/JNK (#9251), p-p44/42 antibody (#9101), and p44/42 antibody (#4695) which were all purchased from Cell Signaling (Danvers, MA).
Uptake of Acetylated LDL
Differentiated THP-1 cells were incubated with 10 M azelnidipine for 48 h to 96 h in culture medium. Then, 25 g/mL DiI-acLDL (Biomedical Technologies) was added to the medium and incubated for a further 4 h at 37 . The fluorescence intensity of cells was measured by WSX-100 (Olympus, Japan) fluorescence microscopy.
siRNA Protocol
Synthetic siRNA for Cav1.2 (Santa Cruz, sc-42688, USA) and the non-specific control pool (Santa Cruz, sc-37007) were purchased from Santa Cruz Biotechnology, and transfection of the RNA oligonucleotide was performed using Lipofectamine RNAiMAX (Life Technologies, 13778-075) according to the supplier's protocol. Briefly, 10 pmol RNAi duplex in the kit were diluted in 100 L Opti-MEM I medium (Gibco, USA) without serum, and 6 L Lipofectamine RNAiMAX was added to each well containing the diluted RNAi duplex and incubated phages play important roles in atherosclerosis 8, 9) . However, the effects of CCBs on macrophage activation remain unclear. In the present study, we aimed to evaluate the effects of azelnidipine, a long-acting dihydropyridine L-type CCB, on the activation of macrophages and to elucidate the mechanisms of action of CCBs on atherosclerosis.
Aim
To investigate the effects and mechanisms of action of azelnidipine in inhibiting the activation and differentiation of THP-1 monocytes.
Methods

Cell Culture and Materials
Human monocytic leukemia cell line THP-1 cells were obtained from Riken Cell Bank (Japan). The cells were maintained in RPMI-1640 medium (Sigma) supplemented with 10% heat-inactivated fetal bovine serum, 2 mM L-glutamine, and 1% penicillin/ streptomycin at 37 under 5% CO2. Fresh medium was replaced twice a week. For general maintenance, the cells were seeded at 1 10 5 cells/mL. THP-1 has been widely used as a model of human monocytes/ macrophages because of its functional and morphological similarities, including its capacity to activate signal transduction pathways. Differentiation of THP-1 cells was induced by treatment with 50 ng/mL phorbol-12-myristate-13-acetate (PMA) (Sigma) in complete RPMI-1640 medium for 24 h. Azelnidipine was provided by Daiichi Sankyo company (Japan). Images were captured by a FSX100 microscope (Olympus, Japan).
Real-Time PCR
Total RNA was isolated using Isogen (Nippon Gene, Japan) according to the manufacturer's instructions. RNA was reverse transcribed using ReverTra Ace (Toyobo, Japan). Quantitative gene expression analysis was performed by real-time PCR in the StepOne Plus system (Applied Biosystems). PCR was performed using TaqMan Gene Expression Assays of lectin-like oxidized LDL receptor-1(LOX-1), matrix metalloproteinase (MMP) 9, apolipoprotein E (Apo E), and CACNA1C (Cav1.2). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was amplified in the same reaction to act as an internal control to normalize the gene expression. TaqMan gene expression assay IDs were as follows: Hs00234579_m1 (MMP9), Hs00171168_m1 (Apo E), Hs01552593_m1 (LOX-1), Hs00167681_m1 (Cav1.2), Hs99999905_m1 (GAPDH). value 0.05 was considered statistically significant.
Results
Azelnidipine Decreased the Adhesion and Differentiation of PMA-Stimulated THP-1 Cells
THP-1 cells were incubated in culture medium in the absence or presence of 10 M azelnidipine for 24 h (Fig. 1A) . In the absence of azelnidipine, most floating THP-1 cells adhered to the culture dish after stimulation with PMA. In contrast, in the presence of azelnidipine, the number of attached THP-1 cells for 5 min at room temperature. Then, 1000 L of medium containing 3 10 5 THP-1 cells were added to each well in 24 well plate with RNAi duplex-Lipofectamine RNAiMAX complexes and incubated for 24 h at 37 .
Statistical Analysis
All experiments were performed at least three times. Mean values for individual experiments were expressed as mean SEM. Statistical differences were analyzed by ANOVA followed by Scheffé's F test or by Student's t-test where appropriate using SPSS. A P azelnidipine that showed astrocytic or spider shape (Fig. 1D) .
Although stimulation with PMA increased the expressions of Apo E (A), MMP9 (B), and LOX-1 (C) mRNA, incubation with azelnidipine for 48 h decreased these expressions by PMA significantly in THP-1 cells (Fig. 2) .
Azelnidipine Suppressed the Function of PMAStimulated THP-1 Cells Fig. 3 shows the uptake of acetylated LDL in THP-1 cells. Azelnidipine inhibited the increase in decreased. The ratio of floating cells to total cells increased from 0.24 to 0.49 (Fig. 1B) . To investigate the dose dependency and time course, we used 0, 1, 10, or 30 M of azelnidipine for up to 4 days. The most effective concentration to prevent adherence of PMA treated THP-1 cells was 10 M; besides treatment of 30 M azelnidipine and 50 ng/mL PMA caused cell deaths (Fig. 1C) . Azelnidipine was still effective for THP-1 differentiation into macrophagelike morphology extended incubation. Those cells treated with azelnidipine remained round shaped even on day 4 compared with the cells not treated with These findings may point to a new antiatherosclerotic property of azelnidipine in patients with hypertension.
Differentiation of THP-1 Cells
THP-1 cells are widely used to investigate the function and regulation of monocytes and macrophages in the cardiovascular system. Monocytes are differentiated in response to inflammation signals in tissues. In vitro, PMA has been reported to activate monocytes into macrophages via PKC activation 10) . the uptake of acetylated LDL by THP-1 cells 48, 72, and 96 h after stimulation with PMA. Azelnidipine also reduced the expression of the adhesion molecules ICAM-1 (Fig. 4A) and LOX-1 (Fig. 4B) . To investigate the signaling pathway, phosphorylation of MAP kinases was investigated (Fig. 4C) . The activation of p38 and JNK were decreased by azelnidipine treatment; however, the reduction of ERK1/2 activation was not apparent.
Cav1.2 and Differentiation of THP-1 Cells
Cav1.2, calcium channel, voltage-dependent, L type, alpha 1C subunit was expressed more than 10-fold in THP-1 cells after PMA stimulation for 24 h (Fig. 5) . Using siRNA of Cav1.2, the expression of Cav1.2 was inhibited by about 67% (Fig. 6A) . The reduction of adhesion of THP-1 was restored by Cav1.2 knockdown (Fig. 6B) , suggesting that the inhibitory mechanism of macrophage differentiation was dependent on the L-type calcium channel pathway.
Discussion
In this study, we demonstrated the inhibitory effects of azelnidipine in a clinical concentration on the differentiation and expression of adhesion molecules and acetylated LDL uptake in THP-1 cells. the macrophage. In Apo E knockout mice, azelnidipine reduced the degree of aortic atherosclerosis, although these phenomena were not observed with amlodipine 6) . These results suggest that azelnidipine has potent antiatherosclerotic properties through inhibition of macrophage activation. In addition, azelnidipine inhibited LOX-1 expression and blocked the uptake of acetylated LDL in macrophages in our study. It may contribute the etiology of favorable effects on atherosclerotic lesion in in vivo models reported previously.
However, siRNA of Cav1.2 blocked the effects of azelnidipine on the adhesion of activated THP-1 cells in our study. Therefore, the antiatherosclerotic effects of azelnidipine may work through Cav1.2.
Study Limitations
We have demonstrated that azelnidipine has potential antiatherosclerotic properties by inhibiting the differentiation of monocytes. However, thus far we have not confirmed whether CCBs reduce or inhibit atherosclerosis in patients. Moreover, it remains uncertain that other CCBs have similar antiatherosclerotic effects in vivo and in vitro. However, some CCBs can suppress cytokine-induced neutrophil activation, leading to the possibility of prevention of the progression of atherosclerosis 19) . Although it is still uncertain whether or not these are class-effects, further studies are warranted in the future.
In the atheroma, foam cells derived from macrophages play the pivotal role in the etiology of atherosclerotic disease. It also remains unclear whether THP-1 cells represent a satisfactory model to mimic However, little is known about the difference between the subsets of monocytes and macrophages. Previous studies reported that Apo E, MMP9, and LOX-1 are upregulated in response to PMA in THP-1 cells 11, 12) and that they activate cell function including phagocytosis and uptake of foreign bodies. In the present study, azelnidipine reduced the PMA-induced expressions of Apo E, MMP9, and LOX-1. In addition, the activation of p-38 and JNK was reduced. It may suggest that azelnidipine decreased inflammatory activation of macrophages. Furthermore, azelnidipine inhibited the uptake of acetylated LDL in THP-1 cells. Therefore, azelnidipine inhibits the PMA-induced differentiation of THP-1 cells into macrophages and also suppresses the function of macrophages.
CCBs and Atherosclerosis
It has been reported that azelnidipine has antiatherosclerotic effects independent of its blood-lowering action in monkeys, mice, and humans 6, 7, 13, 14) . Azelnidipine inhibits MCP-1 expression and the inflammatory response in endothelial cells 15, 16) . Several possible mechanisms including ROS generation 16, 17) , PKC inhibition 18) , and eNOS activation 13) have been reported. Azelnidipine inhibited intracellular ROS generation and reduced VCAM-1 expression and adhesion of monocytes in endothelial cells 16, 17) . It also inhibited adhesion of monocytes to vascular endothelium via PKC inhibition 18) . Moreover, eNOS upregulation was induced by azelnidipine, possibly due to reduction of ROS generation 13) . However, at present, it remains to be established how azelnidipine affects the atherosclerotic process at the functional level of the function and regulation of monocytes and macrophages in cardiovascular biology. However, based on previous studies, THP-1 cell line has a unique property that it can be differentiated into a macrophagelike phenotype by using PMA. THP-1 cells can proliferate rapidly, and experiments are reproducible. Although it is cancellous leukemic cell line which differs from normal primary cells, THP-1 cell line is the almost only monocytic cell line from human species.
For the reasons mentioned above, THP-1 cells are suitable for the study of novel functions and mechanisms in monocyte-macrophages in the cardiovascular system with cautious interpretation and validation using primary cells and/or in vivo models 20) .
Conclusion
The present data suggest that azelnidipine has a pivotal antiatherosclerotic effect on the transformation of human monocytic cells in concentrations that are clinically relevant. Increased expression of adhesion molecules and oxidized LDL receptors with PMA and amplification of LDL uptake in THP-1 cells were inhibited by azelnidipine, which may suppress the differentiation of monocytes. The antiatherosclerotic mechanisms of azelnidipine involved the L-type calcium channel pathway. Thus, azelnidipine may play an important role in reducing atherosclerosis not only by regulating blood pressure but also by preventing the activating of human monocyte/macrophages.
